Tonix Pharmaceuticals (TNXP) announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute, KEMRI, to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 as a vaccine to prevent mpox and smallpox. Tonix will be the sponsor and KEMRI will lead the execution of the proposed clinical trial.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals (TNXP) Q3 Earnings Cheat Sheet
- Tonix Pharma Showcases Promising TNX-801 Vaccine Results
- Tonix Pharmaceuticals presents data on TNX-801 at World Vaccine Congress
- Tonix Pharma Secures Defense Contract for Antiviral Development
- Tonix Pharmaceuticals receives first contract payment from U.S. DoD